Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease11See Editorial by Kalluri, p. 1120  by Hellmark, Thomas et al.
Kidney International, Vol. 55 (1999), pp. 936–944
Identification of a clinically relevant immunodominant region
of collagen IV in Goodpasture disease1
THOMAS HELLMARK, MA˚RTEN SEGELMARK, CHRISTINE UNGER, HARALD BURKHARDT,
JUAN SAUS, and JO¨RGEN WIESLANDER
Department of Nephrology, Lund University, Lund, Sweden; Department of Internal Medicine III, University of Erlangen-
Nu¨rnberg, Erlangen, Germany; FVIB-Instituto de Investigaciones Citolo´gicas Valencia, Spain; and Wieslab AB, Lund, Sweden
Identification of a clinically relevant immunodominant region out lung hemorrhage. The pathogenic process is driven
of type IV collagen in Goodpasture disease. by antibodies to type IV collagen, one of the main struc-
Background. The characteristic feature of Goodpasture dis- tural components of basement membranes. These auto-ease is the occurrence of an autoantibody response to the
antibodies can be detected as circulating antibodies ornoncollagenous domain of the a3 chain of type IV collagen
as linear deposits of IgG in the affected basement mem-[a3(IV)NC1] in the alveolar and glomerular basement mem-
brane. These antibodies are associated with the development branes. Studies have revealed that the major antigenic
of a rapidly progressive glomerulonephritis, with or without epitopes are located in the C-terminal region of the
lung hemorrhage, whereas autoantibodies specific for the other a3(IV) chain [1, 2], one of the six known a(IV) chains
a chains of the heterotrimeric type IV collagen probably do
[3]. In this region, each chain is folded into a globularnot cause disease. In this study, we have investigated whether
domain [4], called the NC1 domain. The limited distribu-differences in fine specificity of autoimmune recognition of the
tion of the a3(IV) chain [5], mainly in glomerular anda3(IV)NC1 correlate with clinical outcome.
Methods. For mapping of antibody binding to type IV colla- alveolar basement membranes, correlates well with the
gen, chimeric collagen constructs were generated in which parts organ involvement in Goodpasture disease.
of the a3(IV)NC1 domain were replaced by the corresponding There are several reports discussing specificity of thesequences of homologous nonreactive a1(IV). The different
Goodpasture autoantibodies and their epitopes. The epi-recombinant collagen chimeras allowed the analysis of anti-
tope has been shown to be a conformational epitope,body specificities in 77 sera from well-documented patients.
Results. One construct that harbors the aminoterminal third depending on intact intrachain disulfide bonds [6]. Epi-
of the a3(IV)NC1 was recognized by all sera, indicating that tope specificity studies on the Goodpasture autoantibod-
it represents the dominant target of the B-cell response in ies have been performed using purified bovine or human
Goodpasture disease. Seventy percent of the samples recog-
antigens [7, 8] and recombinant NC1 domains of thenized other parts of the molecule as well. However, only reac-
different a(IV) chains [9]. These studies all concludetivity to the N-terminus of the a3(IV)NC1 correlated with prog-
that the major epitope is situated on the a3(IV) chain.nosis, that is, kidney survival after six months of follow-up.
Conclusion. The results indicate the crucial importance of More recently, different studies have been published
antibody recognition of this particular domain for the pathogene- [10–13] in which attempts have been made to identify
sis of Goodpasture disease, thereby opening new avenues for the the epitope using synthetic peptides. In one study, the
development of better diagnostic and therapeutic procedures.
last 36 amino acids were proposed as a candidate epitope
[11], but this result has not been supported by others
[12, 13]. Moreover, recombinant proteins expressed in
Goodpasture disease, also referred to as anti-glomeru- Escherichia coli [14–16], as well as the use of recombi-
lar basement membrane (GBM) disease, is characterized nant chimeric proteins expressed in eukaryotic cell lines
by rapidly progressive glomerulonephritis, with or with- [17, 18], suggest that involvement of the N-terminal re-
gion is critical in the autoantibody binding. Thus, the
a3(IV) chain is the major antigen, probably carrying one1 See Editorial by Kalluri, p. 1120
major epitope [7, 19].
Key words: B cell, epitope, glomerular basement membrane, autoanti- In general, approximately 1% of the total IgG fraction
body, rapidly progressive glomerulonephritis. is made up of anti-NC1 antibodies in Goodpasture pa-
tients, and approximately 10% of these are autoantibod-Received for publication February 27, 1998
ies directed against a(IV) chains other than the a3(IV)and in revised form August 24, 1998
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ulonephritis, anti-GBM antibodies are found against the 1999 by the International Society of Nephrology
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NC1 domain of the a1(IV) chain only [12, 20, 21]. In newed every two days; the collection of supernatants
was started when the G-418–resistant cells reached con-fact, there is no strong evidence that autoantibodies
against other chains than the a3(IV) chain can cause dis- fluency. During harvesting, the transfected cells were
kept in fetal calf serum-free DMEM/F12 supplementedease in humans, even though such antibodies can be de-
tected in patients with renal failure. Furthermore, it is with ascorbate [23].
possible that there is one immunodominant epitope region
DNA constructsin the NC1 domain of the a3(IV) chain and that antibodies
We constructed eight chimeric molecules consisting ofto other parts of the molecule carry less pathogenic po-
a type X collagen leader sequence and a triple helix withtential. To test this hypothesis, we investigated the patho-
a type IV collagen NC1 domain. The type X collagengenic impact of autoantibodies to different epitopes. We
cDNA was a kind gift from Prof. K. von der Mark, Erlan-used recombinant chimeric proteins expressed in human
gen, Germany, and the cDNA coding the a1(IV) andembryonic kidney cells (293 cells), in which the a3(IV)
a3(IV)NC1 domains was obtained from J. Saus, Valencia,sequence was changed to the corresponding sequence
Spain. All restriction enzymes and ligase were purchasedfor the a1(IV) chain. Clinical data were retrieved, and
from Boehringer Mannheim (Mannheim, Germany).antibody specificity was correlated to kidney lesions.
The primary type X/type IV collagen chimera was
constructed from a3(IV)NC1 cDNA cloned in pBlue-METHODS
script SK-vector (Stratagene, La Jolla, CA, USA) with
Patients and sera a BamHI site at the 59 end and a NotI site at the 39
Samples that had shown a positive result in routine anti- end and the full-length type X collagen cDNA in the
GBM enzyme-linked immunosorbent assay (ELISA) at pBluescript SK-vector cloned between the HindIII and
Wieslab AB (Lund, Sweden), from 1987 to 1996, to- NotI sites. Both plasmids were cleaved with BamHI and
gether with a few older samples from the serum bank at NotI, and the a3(IV)NC1 cDNA was ligated into the
the Department of Nephrology, Lund University (Lund, internal BamHI site from type X collagen. This construct
Sweden), collected between 1981 and 1987, were chosen contains five unique restriction enzyme sites: a Hind III
and further analyzed in this study. All sera included in site at the 59 end of the construct, a BamHI site at the
this study came from the time of the patients’ presenta- junction between the type X collagen and the type IV
tion and diagnosis. The departments submitting the sam- collagen NC1, HindII and XbaI in the a3(IV)NC1
ples were contacted and asked to submit clinical data cDNA, and a NotI site 39 of the coding DNA (Fig. 1A).
concerning sex, age, renal function at the time of sample The BamHI, HindII, XbaI, and NotI cleavage sites
and six months later, modality and start of treatment, were introduced into the a1(IV)NC1 cDNA using poly-
renal biopsy findings, presence of clinically overt lung merase chain reaction (Perkin-Elmer GeneAmp 2400;
hemorrhage, date of start of dialysis, and date of death. Perkin-Elmer Corp., Foster City, CA, USA), and then
Out of 81 patient sera with anti-GBM antibodies, clinical parts of the a3(IV) chain were exchanged (Fig. 1B). The
records were retrieved for 79 patients. Two patients were primers used are shown in Table 1, and the Pfu-DNA
excluded because of anti-GBM autoantibodies occurring polymerase was purchased from Stratagene. All con-
after transplantation, and thus, 77 patients were available structs were sequenced using the AmpliTaq-FS sequenc-
for this study. Sera from 10 healthy blood donors were ing kit (Perkin-Elmer) and were analyzed with an
used as negative controls. ABI310 automated sequencer (Perkin-Elmer). The con-
structs were cut out using HindIII and NotI and were
Antibodies subcloned into a CMV promoter-driven expression vec-
The monoclonal antibody against type X collagen was tor (pcDNA3; Invitrogen, Leek, The Netherlands; Fig.
supplied by Dr. I. Girkontaite, Erlangen, Germany [22]. 1A). All of the constructs were tested for translation
using an in vitro system (Promega, Madison, WI, USA),
Cell culturing and transfection with a S35-labeled cysteine and a T7RNA polymerase,
HEK-293 cells were cultured in 90 mm cell culture for a protein with correct molecular weight. Before trans-
plates (Nunc, Roskilde, Denmark) in a Dulbecco’s modi- fection, the plasmid DNA was linearized using ScaI.
fied Eagle’s medium:F12 (DMEM:F12) 1:1 medium with
Enzyme-linked immunosorbent assay5% fetal calf serum (GIBCO BRL, Paisley, Scotland,
UK). For each construct, 5 mg of the linearized plasmide Polystyrene microtiter plates (Nunc Immunoplate)
DNA was transfected into 1 3 106 HEK-293 cells using were coated with 100 ml of antigen in coating buffer (50
an electroporator (BioRad, Hercules, CA, USA), with mm sodium carbonate, 0.05% NaN3, pH 9.6). Native type
electrical settings of 200 V, 640mF in a 0.4 cm cuvette. IV collagen NC1 domains were purified as described
The transfected cells were seeded onto a new plate. After elsewhere [7] and were coated at 0.5 mg/ml. The recombi-
48 hours, selection was started by supplementation with nant proteins were diluted to varying degrees in order
to give identical reactions to the antitype X collagen800 mg/ml G-418 (GIBCO BRL). The medium was re-
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Fig. 1. (A) Cloning strategy used to construct
the chimeric constructs, which consist of a type
X collagen triple helix and a type IV collagen
NC1 domain cloned into the CMV-driven
mammalian pcDNA3 expression vector. (B)
Eight different type IV collagen NC1 domains
were constructed. The chimeric constructs
were named 333, 331, 313, 311, 133, 131, 113,
111, according to the origin of the respective
portions of the NC1 domain. For example, the
311 construct is comprised of a type X collagen
triple helix with a type IV collagen NC1 do-
main, having an a3 chain from the BamHI
site at the junction to the HindII site and then
an a1 chain sequence until the end of the
NC1 domain. The corresponding amino acid
sequence for the a3(IV) chain at the junctions
of the different chimeric proteins reads as fol-
lows: for the BamHI site, type X colla-
gen|DPGLKG; for the HindII site, YWL|STP;
for the XbaI site, SPF|LEC; and for the NotI
site, there is no corresponding amino acid se-
quence because it falls 39 of the open reading
frame.
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Table 1. Primers used to introduce restriction enzyme cleavage sites plied to a 10 to 16% SDS-PAGE, and electrophoresis
into the a1(IV) cDNA was carried out as Laemmli described [24].
Primer Immunoblot experiments were performed on samples
number Primer sequence 59-39 direction that were separated with SDS-PAGE and transferred to
1 CATGCTGGATCCGGGGCCCCCAGGCACCA an Immobilone-P membrane (Millipore, Saint-Quentin,
2 GCTGGTGTTGACAGCCAGTACGAGTACTCATT France), using a semidry electroblotter as Burnett de-3 CTGGCTGTCAACCCCTGAGCCCATGCCCATGTC
scribed [25] with certain alterations as we previously4 TGACATTCTAGAAATGGCGCACTTCTAAACTCC
5 CCATTTCTAGAGTGTCACGGCCGTGGGACCTGC described [26]. The membranes were blocked with 2%
6 CCATTCGCCGGCGTTATGTTCTTCTCATACAGAC BSA in coating buffer and were then washed with 0.15 m
NaCl, 0.05% (vol/vol) Tween 20. The primary antibodies
were diluted as discussed earlier here and were incubated
for two hours. After three washings, the membranes
antibody. The plates were then washed three times with were incubated for one hour with secondary antibodies,
0.15 m NaCl, 0.05% (vol/vol) Tween 20. One hundred antimouse IgG-AP, and antihuman IgG-AP, diluted as
microliters of human sera, diluted 1/100 or monoclonal mentioned previously. The membranes were washed and
antibodies diluted 1/1000 in phosphate-buffered saline then developed with nitroblue tetrazolium and 5-bromo-
bovine serum albumin [PBS-BSA; 1.5 mm KH2PO4, 8 4-chloro-3-indolyl phosphate (Sigma).
mm Na2HPO4, 0.12 m NaCl, 2.5 mm KCl, 0.05% (wt/vol)
StatisticsNaN3 containing 0.2% (wt/vol) bovine serum albumin,
pH 7.3] were added to each well. The plates were incu- Statistical evaluation was performed using Student’s
t-test.bated at room temperature for one hour, and after wash-
ing, alkaline phosphatase-conjugated swine antihuman
IgG (Orion Diagnostica AB, Trosa, Sweden) diluted RESULTS
1/500 in PBS-BSA or alkaline phosphatase-conjugated
Immunoblottingrabbit antimouse IgG diluted 1/1000 (Dako, Glostrup,
Eight different chimeric collagen constructs were made,Denmark) was added. Incubation resumed in one hour.
consisting of gene sequences from collagen X, a1(IV),P-nitrophenyl phosphate (1 mg/ml; Sigma Chemical Co.,
and a3(IV), as shown in Figure 1. After transfection ofSt. Louis, MO, USA) in substrate buffer (1 m diethano-
the HEK-293 cells, all constructs yielded clones secretinglamine, 0.5 mm MgCl2, pH 9.8) was used as substrate,
recombinant protein, as measured by anti-collagen Xand color development was measured spectrophotomet-
ELISA. The yield of recombinant proteins ranged fromrically at 405 nm. All assays were run in duplicate, and
0.2 to 2 mg/ml. To ensure that the recombinant proteinswhen standard errors greater than 10% were found, sam-
had the correct molecular weight, immunoblotting exper-ples were reanalyzed.
iments were performed. The anti-type X collagen antibody
recognized a protein migrating with an electrophoreticInhibition enzyme-linked immunosorbent assay
mobility that corresponded to the calculated molecularThe plates were treated as described earlier here, but
weight of approximately 74 kDa for each of the eightthe human sera were diluted at different dilutions in
clones (Fig. 2A). All samples from the patients with anti-
PBS-BSA buffer in order to give the same absorbance
GBM disease tested with this method (N 5 10) showed
after one hour. They were preincubated overnight at 48C a similar pattern, that is, they all recognized recombinant
on a preincubation plate (Nunc lowbinding) with the proteins containing the N-terminal part of the NC1 do-
different inhibitors, that is, recombinant or purified na- main as a3(IV). A typical experiment is shown in Figure
tive proteins in concentrations varying from 0.0025 to 2B. All reactivity of the Goodpasture sera disappears
10 mg/ml. The recombinant proteins were first concen- after reduction of the antigens (data not shown).
trated by precipitating with 50% saturated (NH4)2SO4
and then dissolving and dialyzing them against the PBS- Enzyme-linked immunosorbent assay
BSA buffer. Bound antibodies were detected with alka- Serum samples from all the 77 anti-GBM patients were
line phosphatase-conjugated secondary antibodies as de- tested with ELISA for reactivity to each of the eight
scribed earlier here. recombinant proteins. To calibrate the assays, the
amount of coating material was adjusted to yield an
Sodium dodecyl sulfate-polyacrylamide gel equivalent optical density with the anti-type X collagen
electrophoresis and immunoblotting antibody. A cut-off value was calculated for each of the
One milliliter of the cell supernatants was precipitated chimeric proteins, that is, mean OD plus two standard
with Triton X100 and tricloroacetic acid. The precipitate deviations for the 10 normal blood donors. All 77 patient
was dissolved in sodium dodecyl sulfate-polacrylamide sera showed positive reactions, with recombinant protein
having the a3(IV) sequence in the N-terminal part of thegel electrophoresis (SDS-PAGE) sample buffer and ap-
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Fig. 2. Western blots showing binding of the antitype X collagen antibody (A) and the reactivity of serum from one Goodpasture patient (B). If
the chimeric proteins were reduced. no staining was detected. Data are not shown. Lane 1 contains native purified NC1 domains, and lanes 2
through 9 contain the chimeric proteins 333, 331, 311, 313, 131, 133, 113 and 111, respectively. Patient sera only recognized constructs containing
a3(IV) in the N-terminal portion of the NC1 domain. The arrows indicate the bands of R, the recombinant chimeric proteins; D, the purified
native a3(IV) dimers; and M, the purified native a3 (IV) monomer.
NC1 domain (constructs 333, 311, 331, 313). Reactivity to chimeric proteins and three with high reactivity to 311
but negative for the 131 chimeric protein. The resultsthe four remaining proteins (133, 131, 113, 111) was
generally weak. Nevertheless, values above the cut-off show that all five sera could be inhibited from binding
to native a3(IV)NC1 by virtually 100% with nativevalue were obtained for 53 sera with the 131 and 133
proteins, and 42 sera showed affinity for the 113 and 111 a3(IV)NC1, 333 and 331 chimeric proteins. The two sera
reacting with both the 311 and 131 chimeric proteins inproteins. In Figure 3, the reactivity of all Goodpasture
sera to the different chimeric proteins is shown. Low direct ELISA could be inhibited by approximately 65%
with the 311 chimeric protein and by 40 to 50% usingreactivities to all constructs were expected, as most pa-
tients have cross-reactive and low-affinity antibodies that the 131 chimeric protein as inhibitor. This stands in con-
trast to the three sera reactive to the 311 chimeric proteinalso react with the a1(IV)NC1. Few of the sera showed
reactivities stronger than this background reactivity to only. The 311 construct could inhibit binding to native
a3(IV)NC1 by approximately 85% and the 131 chimericthe 113 chimeric protein, whereas a larger subpopulation
of the samples exhibited an elevated reactivity to the protein only by 20%. Furthermore, neither the 113 con-
struct nor the 111 construct had any inhibiting capacitymiddle portion of the a3(IV)NC1, that is, the 133 and
131 chimeric proteins. on the reactivity of anti-GBM sera to native a3(IV)NC1.
Graphs representing the results obtained with two of the
Inhibition enzyme-linked immunosorbent assay samples are shown in Figure 4. This strongly indicates
that patients recognizing both the 311 and the 131 chime-The direct ELISA showed that the strongest reactivity
was found to the a3(IV) sequences in the N-terminal ric constructs have two separate epitopes: one major
epitope in the N-terminal region and a second minorportion of the NC1 domain. However, a subpopulation
of the sera also exhibited affinity for a3(IV) sequences one in the central region of the a3(IV)NC1.
in the middle portion of the NC1 domain. To elucidate
Correlation between epitope specificity andwhether these interactions were related to a separate
clinical outcomeepitope region in the central part of the a3(IV)NC1
or rather due to nonspecific cross-reactivity, inhibition To elucidate whether antibodies recognizing different
parts of the a3(IV)NC1 domain have the same patho-ELISA experiments were performed. Five sera were
chosen, two with high reactivity to both 311 and 131 genic potential, clinical outcome was compared with
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Fig. 3. The reactivity for all 77 anti-GBM sera to the eight different chimeric proteins as measured by direct ELISA. The baseline indicates the
cut-off value, that is, the mean 1 2 sd for the 10 normal blood donors, calculated for each individual chimeric construct. The mean values are
indicated by horizontal lines.
ELISA results. Six months after the detection of circulat- gion of the a3(IV)NC1 domain compared with the other
regions with clinical outcome. In order to do this, weing anti-GBM antibodies in their serum, 27 patients had
died, 31 patients were on chronic dialysis, and 19 re- divided the optical density for the reaction with the 311
construct by the optical density for the 133 construct.mained alive with a functioning native kidney. To limit
the impact of comorbidity factors, the 27 patients that The ELISA titer ratio 311/133 is a quantitative measure
of the specific autoimmune recognition of the aminoter-died within six months of follow-up were excluded from
the statistical analysis. This analysis revealed that only minal part of a3(IV)NC1 and is accordingly inversely
correlated with kidney survival, as shown in the box plotELISA titers of antibodies with specificity for the amino-
terminal region of the a3(IV)NC1 domain correlated in Figure 5. When comparing the group with a function-
ing native kidney with the group on dialysis, we foundclosely with the incidence of terminal renal insufficiency.
No correlation was found with ELISA reactivities against a significantly lower ratio (P , 0.001); that is, a restricted
epitope specificity to the N-terminal region of thethe central- or C-terminal parts of the a3(IV)NC1 do-
main (Table 2). Patients with fatal outcome also exhib- a3(IV)NC1 domain seems to worsen the prognosis.
We also investigated whether epitope specificity couldited elevation of antibody titers with specificity for the
N-terminal a3(IV)NC1 domain (mean OD was 0.53 to explain why some patients present with lung hemor-
rhage. Clinically, overt lung bleeding was recorded forthe 311 construct). No correlation between ELISA titers
and age of the patients was found. 16 patients in our series. No differences in the epitope
specificity were detected when patients with and withoutAnother way to address the same question was to
correlate antibody specificity for the aminoterminal re- lung bleeding were compared.
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Table 2. Mean values of the reactivity to the
chimeric proteins in ELISA
NFK Dialysis Blood donorsChimeric
construct OD at 405nm
333 0.29860.146a 0.53660.251 0.135 60.019
331 0.35860.258a 0.76560.335 0.106 60.005
311 0.31560.181a 0.63460.277 0.111 60.006
313 0.25460.093a 0.45060.205 0.119 60.005
131 0.25960.098 0.28060.109 0.170 60.022
133 0.32360.215 0.25960.198 0.168 60.030
113 0.17260.067 0.14460.036 0.134 60.003
111 0.14960.051 0.12560.033 0.105 60.008
Data are means 6 sd. The patients were divided into two groups, based on
status after a 6 month follow-up: patients with a functional native kidney (NFK)
and patients on dialysis. The reactivity of the healthy normal blood donors is
shown in the right column.
a Statistically significant difference (P , 0.01) between the two patient groups
Fig. 4. Inhibition ELISA against native purified a3(IV)NC1, using na-
tive a3(IV)NC1 (h), and chimeric protein 333 (1), 331 (n), 311 (s),
131 and 133 (j), and 111 and 113 (d) as inhibitors. (A) This shows an
experiment using a patient serum reactive to 333, 331, 311, and 313
chimeric proteins in direct ELISA, and (B) this shows serum from a
patient that in addition recognized the 131 and 133 chimeric proteins.
Fig. 5. Optical density ratio 311/133 in direct ELISA for the sera from
the anti-GBM patients. In (A), the patients who survived with a native
functional kidney are shown, and in (B), the patients who were on
chronic dialysis after six months of follow-up are shown. The patients
DISCUSSION who died within six months of follow-up showed intermediate values
(mean 1.32 and median 1.15). Ninety-fifth and 75th percentiles areThe major finding in this report is that the most impor-
shown, and the horizontal lines indicate the median values.
tant epitope region for anti-GBM antibodies resides in
the N-terminal third of the NC1 domain of the a3(IV)
chain. This conclusion was reached using a strategy for
making recombinant a3(IV) that conserves conforma- outcome for a comparison of reactivity. Earlier studies
tional epitopes that depend on disulfide bonds and by have clearly indicated that anti-GBM antibodies react
with a conformational epitope(s). The reactivity of theusing a large number of patient sera with known clinical
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antibodies to the antigen is usually abolished if disulfide Many sera also reacted with the middle portion of the
a3(IV)NC1. Inhibition ELISA experiments showed thatbonds are disrupted. For many years, this has prevented
localization of the epitope within the NC1 domain by this reactivity was dependent on autoantibodies recog-
nizing a separate epitope region and did not merely re-enzymatic digestion. Such attempts have resulted in the
loss of antigenicity. Nevertheless, we and others [11–13] flect unspecific cross reactivity. However, the antibodies
to this middle portion seem to be of little or no impor-have tried to localize the epitope using overlapping linear
peptides. We found no region of interest with such an tance to the pathogenesis of the glomerular lesions, as
no correlation between clinical outcome and such anti-approach, and other groups have reported conflicting
results. bodies could be found. Furthermore, our results indicate
that the C-terminal end of the NC1 domain has hardlyIn this study, the replacement of wild-type a3(IV)
sequences with corresponding domains of the a1(IV) any importance for the antigenicity of the molecule. This
finding contradicts the results obtained using syntheticchain enabled the construction of recombinant chimeric
collagen molecules for identification of the immunodom- peptides [11] but is supported by results obtained using
recombinant proteins [14–18]. The 311/133 ratio is aninant region in the Goodpasture antigen. The a1(IV)
chain lacks this major target of autoimmune recognition assay for measuring the fine specificity of anti-GBM anti-
bodies that together with the regular titer gives us anin anti-GBM disease because earlier studies have clearly
shown that less than 10% of the entire antibody response estimate of the toxicity of the sera. Future evaluation is
necessary to determine whether such estimates are help-against type IV collagen, in each individual patient se-
rum, is directed toward the a1(IV) chain [7, 8]. However, ful for clinical decisions, such as dosaging of plasma ex-
changes.a homology of 74% between the a1(IV) and a3(IV)
chains, as well as conserved cysteine positions, enhances A major feature of this study is the large number of
sera used from well-characterized patients. Many factorsthe likelihood of a proper folding of the hybrid con-
structs. The expression of the chimeric constructs in a besides antibody titer and specificity influence the out-
come of anti-GBM disease, such as age, duration of dis-human cell line provides all of the requirements for cor-
rect post-translational modifications and extracellular ease, treatment, renal function at baseline, and comorbid
conditions. Without the available patient data, we mightexport, thereby circumventing some of the disadvantages
of prokaryotic expression systems, for example, the need have been unable to differentiate between the impor-
tance of the two epitope regions. Furthermore, we foundfor denaturing purification procedures for the recombi-
nant proteins. Thus, this method is well suited for the no difference in epitope specificity between patients with
or without lung bleeding. Other factors such as superim-identification of a conformation-dependent antigenic de-
terminant by mutational changes without disturbing the posed respiratory infection, fluid overload, and maybe
smoking seem to be more important for overt lung hem-proper folding of the overall structure. The expressed
chimeric recombinant molecules are recognized by the orrhage than antibody specificity. The largest difference
in titer was found between the group of patients whopatient sera with approximately the same affinity as tis-
sue-purified a3(IV)NC1 domains, and all reactivity is ended up in dialysis and those who retained their native
kidney function. The patients with fatal disease had inter-lost when the recombinant antigens are reduced. Inter-
estingly, the reactivity in the direct ELISA is generally mediate titers, indicating that a parameter for quantity
and specificity of anti-GBM antibodies is highly pre-higher when the C-terminal portion of the NC1 domain
is expressed as a1(IV); for example, the 331 chimera dictive for the fate of kidney function but that it loses
statistical power when death is the outcome parameter.reacts better than the 333 construct. This could be due
to a slightly different folding, resulting in a more denatur- However, death is dependent on a variety of comorbid
conditions such as age, sequelae of uremia, and sideated protein that has a higher affinity for the autoanti-
bodies [12]. effects of treatment. In this respect, the cohort of patients
that died differed significantly in age (69 6 10) from theAll sera tested with ELISA reacted with constructs
containing the a3(IV) sequence in the N-terminal end patients that survived with terminal renal insufficiency
(54 6 17) or with native kidney function (53 6 21).of the NC1 domain. Immunoblotting experiments showed
the same results for all 10 sera tested using this method. Therefore, age is an important comorbidity factor that
is likely to have a strong and independent impact onWhen constructs containing the a3(IV) sequence at the
N-terminal end of the NC1 domain were used in inhibi- mortality in this cohort of patients and may account for
a weaker association of the pathogenicity profile of thetion experiments, reactivity to the native a3 chain of
type IV collagen was abolished or strongly diminished. autoantibodies with loss of life than with loss of renal
function.High reactivity in ELISA to such constructs correlated to
an adverse outcome regarding renal function. Together, The restricted reactivity of the autoantibodies from
different patients strongly indicates an antigen-driventhese findings strongly indicate that a major pathogenic
epitope region is located in this portion of the molecule. autoimmune process. Whether this autoimmune recogni-
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